share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 First Quarter Results

沃尔格林-联合博姿 | 8-K:沃尔格林靴子联盟公布2024财年第一季度业绩

美股sec公告 ·  01/04 00:00
Moomoo AI 已提取核心信息
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company...Show More
On January 4, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the first fiscal quarter ending November 30, 2023. The company announced a net loss of $67 million, a significant improvement from the $3.7 billion net loss in the previous year's quarter. This improvement was primarily due to the absence of a $6.5 billion pre-tax charge for opioid-related claims and litigation recorded in the year-ago quarter. Despite the net loss, WBA saw a 10% increase in sales year-over-year, reaching $36.7 billion. The adjusted earnings per share (EPS) decreased by 43.1% to $0.66, influenced by challenging retail market trends in the U.S. and a higher tax rate. WBA also declared a 48% reduction in its quarterly dividend payment to $0.25 per share. The company maintained its fiscal 2024 adjusted EPS guidance of $3.20 to $3.50, expecting underlying earnings growth to be offset by various factors including a higher tax rate and lower COVID-19 contributions. The U.S. Healthcare segment reported a sales increase to $1.9 billion, with VillageMD and Shields driving growth. The U.S. Retail Pharmacy segment saw a 6.4% increase in sales, while the International segment's sales rose by 12.4%. WBA's CEO Tim Wentworth emphasized the company's focus on strategic options to drive long-term shareholder value, cost management, and cash flow improvement.
2024年1月4日,Walgreens Boots Alliance, Inc.(WBA)公布了截至2023年11月30日的第一财季财务业绩。该公司宣布净亏损6700万美元,与去年同期的37亿美元净亏损相比有了显著改善。这种改善主要是由于去年同期记录的与阿片类药物相关的索赔和诉讼没有65亿美元的税前费用。尽管出现净亏损,但WBA的销售额同比增长了10%,达到367亿美元。受美国零售市场充满挑战的趋势和更高的税率的影响,调整后的每股收益(EPS)下降了43.1%,至0.66美元。WBA还宣布将季度股息支付减少48%,至每股0.25美元。该公司维持其2024财年调整后的每股收益预期为3.20美元至...展开全部
2024年1月4日,Walgreens Boots Alliance, Inc.(WBA)公布了截至2023年11月30日的第一财季财务业绩。该公司宣布净亏损6700万美元,与去年同期的37亿美元净亏损相比有了显著改善。这种改善主要是由于去年同期记录的与阿片类药物相关的索赔和诉讼没有65亿美元的税前费用。尽管出现净亏损,但WBA的销售额同比增长了10%,达到367亿美元。受美国零售市场充满挑战的趋势和更高的税率的影响,调整后的每股收益(EPS)下降了43.1%,至0.66美元。WBA还宣布将季度股息支付减少48%,至每股0.25美元。该公司维持其2024财年调整后的每股收益预期为3.20美元至3.50美元,预计基础收益增长将被包括更高税率和 COVID-19 缴款减少在内的各种因素所抵消。美国医疗保健板块报告销售额增长至19亿美元,VillageMD和Shields推动了增长。美国零售药房板块的销售额增长了6.4%,而国际板块的销售额增长了12.4%。WBA首席执行官蒂姆·温特沃斯强调了公司专注于战略选择,以推动长期股东价值、成本管理和现金流改善。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息